title: Brachytherapy radiation doses to the neurovascular bundles.
abstract: OBJECTIVE
  To investigate the role of radiation dose to the neurovascular bundles (NVB) in brachytherapy-related impotence.
  
  
  METHODS
  Fourteen Pd-103 or I-125 implant patients were studied. For patients treated with implant alone, the prostate and margin (clinical target volume [CTV]) received a prescription dose of 144 Gy for I-125 or 115 Gy for Pd-103. Two patients received Pd-103 (90 Gy) with 46 Gy supplemental external beam radiation (EBRT). Axial CT images were acquired 2 to 4 hours postoperatively for postimplant dosimetry. Because the NVBs cannot be visualized on CT, NVB calculation points were determined according to previously published anatomic descriptions. Bilateral NVB points were considered to lie posterior-laterally, approximately 2 mm from the prostatic capsule. NVB doses were recorded bilaterally, at 0.5-cm intervals from the prostatic base.
  
  
  RESULTS
  For Pd-103, the average NVB doses ranged from 150 Gy to 260 Gy, or 130% to 226% of the prescription dose. For I-125, the average NVB dose ranged from 200 Gy to 325 Gy, or 140% to 225% of the prescription dose. These was no consistent relationship between the NVB dose and the distance from the prostatic base. To examine the possible effect of minor deviations of our calculation points from the true NVB location, we performed NVB calculations at points 2 mm medial or lateral from the NVB calculation point in 8 patients. Doses at these alternate calculation points were comparable, although there was greater variability with small changes in the calculation point if sources were located outside the capsule, near the NVB calculation point. Three patients who developed early postimplant impotence had maximal NVB doses that far exceeded the average values.
  
  
  CONCLUSIONS
  In the next few years, we hope to clarify the role of high NVB radiation doses on potency, by correlating NVB dose calculations with a large number of patients enrolled in an ongoing I-125 versus Pd-103 trial for early-stage patients, for whom detailed dosimetric and potency data are being collected prospectively. In the future, we anticipate that NVB doses may be incorporated into dosimetry guidelines to maximize tumor control and minimize treatment-related morbidity.
authors.affiliation: Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA.
authors.forename: S J
authors.initials: SJ
authors.lastname: DiBiase
authors.forename: K
authors.initials: K
authors.lastname: Wallner
authors.forename: K
authors.initials: K
authors.lastname: Tralins
authors.forename: S
authors.initials: S
authors.lastname: Sutlief
mesh_terms: D001918:Brachytherapy / Q000009:adverse effects*; D007172:Erectile Dysfunction / Q000209:etiology*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D055585:Physical Phenomena; D010825:Physics; D010984:Platinum / Q000627:therapeutic use; D011467:Prostate / Q000098:blood supply* / Q000000981:diagnostic imaging / Q000294:innervation*; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000532:radiotherapy*; D011829:Radiation Dosage; D011832:Radiation Injuries / Q000150:complications*; D011868:Radioisotopes / Q000627:therapeutic use; D015203:Reproducibility of Results; D014057:Tomography, X-Ray Computed
chemical_list: D007457:Iodine Radioisotopes; D011868:Radioisotopes; D010984:Platinum